# PET/CT with ^{18}F-FLT: Does It Improve the Therapeutic Management of Metastatic Germ Cell Tumors?

Christina Pfannenberg[1], Philip Aschoff[1], Helmut Dittmann[1], Frank Mayer[2], Gerald Reischl[3], Claus von Weyhern[4], Lothar Kanz[2], Claus D. Claussen[1], Roland Bares[1], and Joerg T. Hartmann[2]

[1]Department of Radiology and Nuclear Medicine, University of Tuebingen, Tuebingen, Germany; [2]Department of Hemato-Oncology, University of Tuebingen, Tuebingen, Germany; [3]Section of Radiopharmacy, University of Tuebingen, Tuebingen, Germany; and [4]Department of Pathology, University of Tuebingen, Tuebingen, Germany

Because ^{18}F-FDG PET alone has only limited value in metastatic germ cell tumors (GCTs), we investigated the addition of 3′-deoxy-3′-^{18}F-fluorothymidine (FLT) to ^{18}F-FDG for early response monitoring and prediction of the histology of residual tumor masses in patients with metastatic GCT. **Methods:** Eleven patients with metastatic GCT were examined with both ^{18}F-FDG PET/CT and ^{18}F-FLT PET/CT before chemotherapy, after the first cycle of chemotherapy (early response), and 3 wk after completion of chemotherapy. In 1 patient with negative ^{18}F-FLT PET/CT results before chemotherapy, no further ^{18}F-FLT scanning was performed. PET images were analyzed visually and, using standardized uptake values (SUVs), semiquantitatively. The results were compared with the findings of CT and tumor marker levels and validated by histopathologic examination of resected residual masses, including Ki-67 immunostaining (7 patients), or by clinicoradiologic follow-up for at least 6 mo (4 patients). A responder was defined as a patient showing the presence of necrosis, a complete remission, or a marker-negative partial remission within a minimum progression-free interval of 6 mo. Early treatment response was judged according to the criteria of the European Organization for Research and Treatment of Cancer. **Results:** Before chemotherapy, reference lesions showed increased ^{18}F-FDG uptake (mean SUV, 8.8; range, 2.9–15.0) in all patients and moderate ^{18}F-FLT uptake (mean SUV, 3.7; range, 1.7–9.7) in 10 of 11 patients. After 1 cycle of chemotherapy, mean SUV decreased in responders and nonresponders by 64% and 60%, respectively, for ^{18}F-FDG ($P = 0.8$) and by 58% and 48%, respectively, for ^{18}F-FLT ($P = 0.5$). After the end of chemotherapy, mean SUV decreased in responders and nonresponders by 85% and 73%, respectively, for ^{18}F-FDG ($P = 0.1$) and by 68% and 65%, respectively, for ^{18}F-FLT ($P = 0.8$). The results of early and final PET were inconsistent in 6 of 11 patients for ^{18}F-FDG and in 4 of 10 patients for ^{18}F-FLT. Both patients with teratoma had false-negative results on both ^{18}F-FDG and ^{18}F-FLT. The sensitivity, specificity, positive predictive value, and negative predictive value for detection of viable tumor after 1 cycle of chemotherapy were 60%, 33%, 43%, and 50%, respectively, for ^{18}F-FDG and 60%, 80%, 75%, and 67%, respectively, for ^{18}F-FLT PET/CT. The respective values after the end of chemotherapy were 20%, 100%, 100%, and 60% for ^{18}F-FDG and 0%, 100%, 0%, and 50% for ^{18}F-FLT PET/CT. **Conclusion:** PET-negative residual masses after chemotherapy of metastatic GCT still require resection, since the low negative predictive value of ^{18}F-FDG PET for viable tumor cannot be improved by application of ^{18}F-FLT.

**Key Words:** germ cell tumor; therapy monitoring; ^{18}F-FDG PET; ^{18}F-FLT PET; residual mass; teratoma

Through the application of cisplatin-based chemotherapy followed by secondary resection of residual masses, 70%−80% of patients with metastatic germ cell tumor (GCT) can be cured. Patients with poor-prognosis GCT according to the classification of the International Germ Cell Cancer Collaborative Group (*1*), however, have distinctly lower cure rates, with a 5-y overall survival of approximately only 48% after standard therapy (*2*). In an attempt to improve these results, high-dose chemotherapy with autologous stem cell support has been applied (*3,4*). A benefit was identified especially for those patients with an inadequate tumor marker decline after the first 2 cycles of conventional chemotherapy (*4*). These data underline the importance of a reliable assessment of early tumor response. The marker decline is the only tool of response evaluation that has been used to guide therapy. However, tumor markers are not always elevated. Furthermore, after chemotherapy, residual masses beyond 1 cm in diameter will be detectable in about 40% of the patients. These residues contain either necrosis or fibrosis but may also contain viable invasive GCT in mature teratomas (*5*). Resectioning of viable tumor is a means to eradicate residual tumor cells that could give rise to a relapse. Eliminating mature teratoma reduces the risk that either a growing-teratoma syndrome or a secondary GCT will develop. At the same time, resectioning of pure necrosis or fibrosis is probably of no benefit to the patient. To date, no

diagnostic tool has been developed that reliably predicts the contents of the residual mass. Changes in GCT morphology documented by CT or MRI and the decline of tumor marker levels do not correctly differentiate between the different histologies (*6*). Because of its assessment of tumor biology, PET may offer additional diagnostic information for the prediction of therapy response and the classification of residual masses in patients with metastatic GCT (*7*). Up to now, $^{18}$F-FDG has been the only radiotracer used for imaging of GCT. Increased uptake of $^{18}$F-FDG is regarded as an indicator of viable tumor. However, $^{18}$F-FDG uptake is not specific for tumor; inflammatory and granulomatous tissues also show $^{18}$F-FDG accumulation (*8*). Several studies assessing the role of $^{18}$F-FDG PET in seminomas found a significant advantage of this modality over CT in evaluating postchemotherapy residues. However, the role of $^{18}$F-FDG PET in staging nonseminomatous residues is limited because $^{18}$F-FDG PET cannot differentiate mature teratoma from necrosis and fibrosis (*6,7,9–12*). In predicting early therapy response, $^{18}$F-FDG PET may have a role in poor-prognosis GCT patients, as has been addressed in a pilot study with 19 patients (*13,14*).

The thymidine analog 3′-deoxy-3′-$^{18}$F-fluorothymidine (FLT) is a cell proliferation marker. The tracer is trapped within the cell after phosphorylation by thymidine kinase 1, the key enzyme in the salvage pathway of DNA synthesis (*15,16*). Therefore, the accumulation of $^{18}$F-FLT depends on the expression of thymidine kinase 1, which is closely associated with cell proliferation. Increased uptake of $^{18}$F-FLT has been shown in various tumors (*17–21*).

Because of the limitations of $^{18}$F-FDG PET in differentiating between viable tumor, teratoma, and necrosis or fibrosis, we performed $^{18}$F-FLT PET/CT in addition to $^{18}$F-FDG PET/CT in patients with advanced metastatic GCT. The aim was to compare the diagnostic efficacy of $^{18}$F-FLT PET/CT with that of $^{18}$F-FDG PET/CT for early response monitoring and prediction of residual viable tumor after chemotherapy of metastatic GCT.

## MATERIALS AND METHODS

### Patients

The PET/CT data of 11 consecutive treated men with a mean age of 38 y (range, 23–48 y) and histologically proven metastatic GCT (10 nonseminoma and 1 seminoma, all with gonadal primary) were analyzed. According to the classification of the International Germ Cell Cancer Collaborative Group, the group comprised 6 patients with poor-prognosis GCT, 4 with intermediate-prognosis GCT, and 1 with good-prognosis GCT. All but 2 patients presented with multiple metastatic sites: abdomen ($n = 9$), mediastinum ($n = 6$), lung ($n = 5$), liver ($n = 2$), bone ($n = 2$), and central nervous system ($n = 1$). In all patients, $^{18}$F-FLT PET/CT was performed 1–3 d after $^{18}$F-FDG PET/CT. In patients with increased tumor $^{18}$F-FLT uptake in the pretreatment scan, $^{18}$F-FLT PET/CT was repeated after the first cycle of chemotherapy (early response) and 3 wk after completion of chemotherapy (Fig. 1). According to local patient management standards, an additional interim staging by only CT took place after the second cycle. Routine staging also included evaluation of the tumor markers β-human chorionic gonadotropin, α-fetoprotein, and lactate dehydrogenase before each cycle and after completion of chemotherapy. Patients with poor-prognosis GCT received 4 cycles of sequential first-line high-dose chemotherapy plus autologous stem cell support. Patients with recurrent disease were treated with 3 cycles of standard-dose chemotherapy followed by 1 cycle of high-dose chemotherapy and stem cell support. Whenever technically feasible, all residual tumors were resected after completion of chemotherapy (*22,23*). Follow-up included CT and serum tumor markers every 3 mo after completion of therapy. The PET/CT examinations were performed according to our institutional guidelines, with all patients giving written informed consent. The study protocol was approved by the local Ethics Committee.

### PET/CT

The radiotracer $^{18}$F-FLT was synthesized at our radiopharmacy department as previously described (*24*). For $^{18}$F-FDG PET, all patients fasted at least 6 h before examination. The injected dose of $^{18}$F-FDG and $^{18}$F-FLT varied between 350 and 400 MBq according to patient weight. Blood glucose was measured before injection of $^{18}$F-FDG to ensure normal blood glucose levels below 120 mg/dL. During the 60-min uptake phase, the patients were given a negative oral contrast agent (1.0–1.5 L mannitol, 2%) for optimal bowel opacification.

In all patients, PET/CT was performed using the Hi-Rez Biograph 16 (Siemens Medical Solutions), consisting of a high-resolution 3-dimensional lutetium oxyorthosilicate PET scanner and a 16-row multidetector CT scanner. Emission data were acquired for 6–8 bed positions, typically covering the base of the skull to the upper thigh, with a 3-min acquisition per field of view. CT was operated at a peak voltage of 120 kV, tube current of 120–250 mAs, rotation time of 0.5 s, collimation of 0.75 mm (thorax)



**FIGURE 1.** Schedule of $^{18}$F-FDG PET/CT and $^{18}$F-FLT PET/CT for response monitoring and evaluation of residual masses during and after chemotherapy in 11 patients with metastatic GCT.

and 1.5 mm (abdomen), and table feed of 12 and 24 mm, respectively. All ^{18}F-FDG PET/CT examinations before and after chemotherapy included single-phase contrast-enhanced CT with intravenous administration of 120 mL of iodinated contrast agent (Ultravist 370; Schering) to obtain diagnostic CT data. To reduce the radiation burden, all ^{18}F-FLT studies and the ^{18}F-FDG PET/CT study after the first cycle were performed without intravenous contrast and included an ultra low dose (30 mAs) CT scan only.

The CT data were used for attenuation correction of PET images. PET images were reconstructed using an iterative algorithm (ordered-subset expectation maximization: 2 iterations, 8 subsets). The reconstructed PET, CT, and fused images were displayed with commercially available software.

### Image Analysis

The ^{18}F-FDG and ^{18}F-FLT PET/CT images were evaluated retrospectively, lesion by lesion, by 2 experienced nuclear medicine specialists and 2 experienced CT radiologists working in consensus. The readers were not aware of the histopathologic, clinical, or other imaging findings. Uptake of ^{18}F-FDG and ^{18}F-FLT in the metastatic lesions was evaluated visually and semiquantitatively. On PET images, any focal tracer uptake exceeding normal regional tracer accumulation was regarded as positive and indicative of viable tumor (carcinoma or teratoma), whereas lesions without ^{18}F-FDG or ^{18}F-FLT uptake were classified as negative and indicative of nonviable tumor tissue (necrosis or fibrosis). For semiquantitative analysis, 3-dimensional regions of interest were placed over the tumor semiautomatically using a dedicated software program, with a threshold of 50% of the maximum tracer uptake. According to the formula "standardized uptake value (SUV) = measured activity concentration (Bq/mL)/injected activity (Bq) per body volume (cm$^3$)," the maximum SUV (SUVmax) and mean SUV (SUVmean) were calculated from each region of interest. SUVmean denotes the mean uptake averaged over all voxels in the tumor region of interest. In patients with multiple tumor sites, the lesion with the highest tracer uptake was selected as a reference lesion for the comparative analysis.

### Ki-67 Immunohistochemistry

To evaluate the relationship between PET results and direct measurement of proliferation, Ki-67 immunohistochemical staining was performed on 7 tumor specimens obtained from patients who had undergone a surgical resection of residual masses. Formalin-fixed and paraffin-embedded tumor samples were sectioned and immunostained using the monoclonal anti–Ki-67 antibody (clone MIB-1, 1:400; Dako). The MIB-1 index was calculated as the ratio of the number of Ki-67–positive cells to the total number of cells.

### Statistical Analysis

The PET findings were compared with histologic results or imaging follow-up. In patients who underwent resection, histopathologic results were used as the reference. A nonresponder was defined as a patient showing viable residual tumor and mature teratoma, a documented CT progression, or increasing tumor marker levels within a minimum follow-up period of 6 mo without resection of residual tumor masses. A responder was defined as a patient showing the presence of necrosis, a documented complete remission, or a marker-negative partial remission on CT within a minimum follow-up period of 6 mo without resection of residues. In cases of multiple resections, the most unfavorable histology was considered.

For early assessment of tumor response by PET, we used the preliminary criteria of the European Organization for Research and Treatment of Cancer (EORTC). According to these, a reduction of tumor ^{18}F-FDG uptake (SUV) to a minimum of 10%−25% after 1 cycle of chemotherapy is considered to indicate metabolic response (25). Because there are no established response criteria for ^{18}F-FLT, we used the same criteria for ^{18}F-FLT as for ^{18}F-FDG. Differences in SUVs between responder and nonresponder were evaluated using the 2-sided $t$ test for independent probe samples. $P$ values of less than 0.05 were considered statistically significant.

For both ^{18}F-FDG PET/CT and ^{18}F-FLT PET/CT, sensitivity, specificity, positive and negative prognostic predictive values, and accuracy were determined after 1 cycle and after completion of chemotherapy on a per-patient basis. If necrosis was found on histologic examination and the patient experienced progression-free survival, negative imaging findings were considered true-negative; if viable carcinoma and teratoma were found on histologic examination and relapse occurred within 6 mo, positive imaging finding were considered true-positive.

### RESULTS

The 11 patients with advanced GCT underwent a total of 64 PET/CT examinations, including 33 with ^{18}F-FDG and 31 with ^{18}F-FLT. In a single patient with no distinct ^{18}F-FLT tumor uptake on the pretreatment scan, no subsequent ^{18}F-FLT examination was performed. The results of PET/CT were validated by histopathologic examination of resected residual masses in 7 patients and by clinicoradiologic follow-up in 4 patients. The median follow-up interval for patients without surgical resection of residual masses was 527 d (range, 206–1,337 d). Eight of 11 patients remained progression-free for at least 6 mo after treatment; in 5 of the 8 patients, histopathologic examination of the resected mass revealed necrosis ($n = 3$) or mature teratoma ($n = 2$). In the remaining 3 patients, clinical and imaging follow-up demonstrated no signs of relapse within a follow-up period of 1,337, 325, and 206 d. Three of 11 patients progressed between days 241 and 293 after completion of chemotherapy. In 2 of the 3 patients, histopathologic examination of resected residues revealed viable residual tumor confirmed by immunohistochemistry. If residual tumor was present, the proliferation index was determined by MIB-1 index. The third patient had no surgery. Details of patient characteristics, the PET/CT evaluation, and treatment results are listed in Table 1.

### Pretreatment Analysis

In the patient-based analysis of pretreatment scans, all patients showed increased ^{18}F-FDG uptake in the reference lesions, with a mean SUVmean and a mean SUVmax of 8.8 and 14.6, respectively (ranges, 2.9–15.0 and 5.1–23.7, respectively). In comparison to ^{18}F-FDG, the ^{18}F-FLT uptake was moderate, with a mean SUVmean and a mean SUVmax of 3.7 and 5.8, respectively (ranges, 1.7–9.7 and 4.6–11.4, respectively). A single patient was ^{18}F-FLT–negative. Most reference lesions showed marked heterogeneous tracer uptake without any visible correlation between

**TABLE 1.** Patient Characteristics, PET/CT Findings, and Outcome

| Patient no. | Age (y) | Histology | Regime | Prognosis (IGCCCG) | AFP | β-HCG | LDH | Tracer | SUV$_{max}$ | SUV$_{mean}$ | ΔSUV$_{mean}$ (%) | SUV$_{max}$ | SUV$_{mean}$ | CT/TM | Treatment result | MIB-1 index (%) | R/NR | Follow-up (d) | Relapse |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 45 | NS | HD-CE | Intermediate | 196 | 175 | 253 | 18F-FDG | 23.7 | 14.8 | −89 | 1.6 | 1.5 | PRm− | CR | NA | R | 1,337 | No |
|  |  |  |  |  |  |  |  | 18F-FLT | 11.4 | 7.1 | −79 | 1.6 | 1.2 |  |  |  |  |  |  |
| 2 | 31 | NS | HD-PEI | Poor | 34,384 | 143 | 360 | 18F-FDG | 18.3 | 11.6 | −67 | 4.4 | 2.6 | SD | VC | 1 | NR | 293 | Yes |
|  |  |  |  |  |  |  |  | 18F-FLT | 9.8 | 9.7 | −70 | 2.6 | 1.3 |  |  |  |  |  |  |
| 3 | 48 | NS | PEB | Intermediate | 4,563 | 9.8 | 236 | 18F-FDG | 12.4 | 5.5 | −56 | 4.2 | 2.3 | SD | TER | 20 | NR | 1,030 | No |
|  |  |  |  |  |  |  |  | 18F-FLT | 6.3 | 2.8 | −14 | 3.4 | 1.4 |  |  |  |  |  |  |
| 4 | 30 | NS | HD-PEI | Poor | 1,179 | 59,876 | 511 | 18F-FDG | 5.1 | 2.9 | −14 | 2.5 | 1.4 | PRm− | VC | 70 | NR | 238 | Yes |
|  |  |  |  |  |  |  |  | 18F-FLT | 4.6 | 2.0 | −35 | 1.9 | 0.7 |  |  |  |  |  |  |
| 5 | 39 | NS | HD-PEI | Poor | 50 | 890 | 3,650 | 18F-FDG | 14.8 | 9.6 | −75 | 1.8 | 1.4 | CR | CR | NA | R | 325 | No |
|  |  |  |  |  |  |  |  | 18F-FLT | 6.6 | 3.4 | −24 | 2.3 | 1.0 |  |  |  |  |  |  |
| 6 | 46 | NS | HD-PEI | Poor | 688 | 0.54 | 1,235 | 18F-FDG | 15.2 | 9.0 | −29 | 1.9 | 1.1 | PRm− | NEC | <1 | R | 540 | No |
|  |  |  |  |  |  |  |  | 18F-FLT | 1.0 | 1.0 | NA | NA | NA |  |  |  |  |  |  |
| 7 | 41 | S | PEB | Good | 1 | 2 | 2,293 | 18F-FDG | 14.5 | 8.5 | −74 | 1.7 | 1.5 | PRm− | PRm− | NA | R | 206 | No |
|  |  |  |  |  |  |  |  | 18F-FLT | 5.6 | 4.7 | −64 | 2.0 | 1.2 |  |  |  |  |  |  |
| 8 | 41 | NS | TIP | Intermediate | 420 | 5,612 | 564 | 18F-FDG | 21.0 | 15 | −86 | 2.7 | 1.2 | PRm− | DoD | NA | NR | 241 | Yes |
|  |  |  |  |  |  |  |  | 18F-FLT | 5.4 | 3.0 | −67 | 1.9 | 0.9 |  |  |  |  |  |  |
| 9 | 22 | NS | HD-PEI | Poor | 21,497 | 3.5 | 248 | 18F-FDG | 12.0 | 7.7 | −55 | 2.3 | 1.2 | PRm− | NEC | <1 | R | 683 | No |
|  |  |  |  |  |  |  |  | 18F-FLT | 5.4 | 3.2 | −43 | 2.1 | 1.3 |  |  |  |  |  |  |
| 10 | 34 | NS | HD-PEI | Poor | 1,787 | 38,300 | 514 | 18F-FDG | 13.5 | 6.1 | −62 | 2.7 | 1.2 | PRm− | NEC | <1 | R | 324 | No |
|  |  |  |  |  |  |  |  | 18F-FLT | 5.2 | 2.6 | −73 | 2.1 | 1.3 |  |  |  |  |  |  |
| 11 | 36 | NS | PEB | Intermediate | 989 | 6,135 | 573 | 18F-FDG | 10.0 | 5.7 | −79 | 2.1 | 1.0 | PRm+ | TER | 2 | NR | 542 | No |
|  |  |  |  |  |  |  |  | 18F-FLT | 2.9 | 1.7 | −53 | 1.5 | 0.8 |  |  |  |  |  |  |

IGCCCG = International Germ Cell Cancer Collaborative Group; TM = tumor marker; AFP = α-fetoprotein (ng/mL); β-HCG = β-human chorionic gonadotropin (U/L); LDH = lactate dehydrogenase (U/L); R = responder; NR = nonresponder; NS = nonseminoma; HD-CE = high-dose carboplatin and etoposide; PRm− = marker-negative partial remission; CR = complete remission; NA = not applicable; HD-PEI = high-dose cisplatin, etoposide, and ifosfamide; SD = stable disease; VC = vital carcinoma; PEB = cisplatin, etoposide, and bleomycin; TER = teratoma; NEC = necrosis; TIP = paclitaxel, ifosfamide, and cisplatin; S = seminoma; DoD = death of disease; PRm+ = marker-positive partial remission.

the uptake patterns of $^{18}$F-FDG and $^{18}$F-FLT in corresponding lesions (Figs. 2 and 3A–3C).

### Early Response Monitoring

After 1 cycle of chemotherapy (early response), all patients showed a reduction of both $^{18}$F-FDG and $^{18}$F-FLT uptake in the reference lesions, indicating a metabolic tumor response according to the proposed EORTC criteria (Figs. 2 and 3D–3F). The mean SUVmean of $^{18}$F-FDG decreased from 8.8 at baseline to 2.8 (range, 1.2–6.4; ΔSUVmean, −62%; range, 14%−89%), and the mean SUVmean of $^{18}$F-FLT decreased from 3.7 at baseline to 1.7 (range, 0.7–2.9; ΔSUVmean, −52%; range, 14%−79%). There was basically no difference in the decrease of SUV between responders and nonresponders for $^{18}$F-FDG (ΔSUVmean, −64% vs. −60%; $P = 0.8$), and there was no significant

difference for $^{18}$F-FLT (ΔSUVmean, −58% vs. −48%; $P = 0.5$).

### Posttreatment Analysis

After completion of chemotherapy, the SUVs further decreased to a mean SUVmean of 1.5 for $^{18}$F-FDG (range, 1.0–2.6; ΔSUVmean, −80%, and range, 52%−92%) and a mean SUVmean of 1.1 (near background level) for $^{18}$F-FLT (range, 0.7–1.4; ΔSUVmean, −63%, and range, 53%−73%) (Figs. 2 and 3G–3I). After completion of chemotherapy, there was a tendency similar to that after 1 cycle, with hardly any difference in the decrease in SUV between responders and nonresponders for $^{18}$F-FDG (SUVmean, 85% vs. 73%; $P = 0.1$) or for $^{18}$F-FLT (SUVmean, 68% vs. 65%; $P = 0.8$), just a slight trend. No tumor showed an increase in $^{18}$F-FLT uptake at any time during or after therapy.

The results of early and final predictions of response were inconsistent in 6 of 11 patients on $^{18}$F-FDG PET and in 4 of 10 patients on $^{18}$F-FLT PET. In all 5 patients in whom viable tumor or teratoma was found on histologic examination of resected masses or who had early relapse during follow-up, the residual masses failed to show any $^{18}$F-FLT uptake. There was also no $^{18}$F-FDG uptake in 4 of these patients, resulting in a false-negative lesion classification. One patient with histologically proven viable tumor was correctly classified with $^{18}$F-FDG PET (Figs. 3G–3I and 4). The 2 patients with teratoma on histologic examination showed false-negative results on both $^{18}$F-FDG PET and $^{18}$F-FLT PET. All 6 patients with necrosis on histologic examination ($n = 3$) or progression-free follow-up ($n = 3$) were correctly classified as true-negative on both $^{18}$F-FDG PET and $^{18}$F-FLT PET. The sensitivity, specificity, accuracy, and positive and negative predictive values of $^{18}$F-FDG and $^{18}$F-FLT PET for prediction of response and classification of residual masses are summarized in Table 2.

In the group of responding patients (necrosis on histologic examination and progression-free survival), the Response Evaluation Criteria in Solid Tumors showed 5 with marker-negative partial remission and 1 with complete remission on CT. In the group of nonresponders (viable carcinoma and teratoma on histologic examination and relapse within 6 mo), there were 2 patients with stable disease, 2 with marker-negative partial remission on CT, and 1 with marker-positive partial remission on CT.

### Ki-67 Immunohistochemistry

The MIB-1 labeling index for the 7 resected tissue samples showed a wide variation, ranging from less than 1% for patients with necrosis on histology to 70% in 1 patient with viable residual lung metastases (Table 1). Analysis indicated no correlation between the MIB-1 index and $^{18}$F-FLT SUVmax ($r = 0.12$, $P = 0.82$) or Δ$^{18}$F-FLT SUVmean after therapy ($r = 0.13$, $P = 0.80$). There was also no correlation between the MIB-1 index and $^{18}$F-FDG SUVmax ($r = 0.30$, $P = 0.52$) but a positive correlation



**FIGURE 2.** Changes in tumor uptake of $^{18}$F-FDG (A) and $^{18}$F-FLT (B) (SUVmean) after 1 cycle and after end of chemotherapy for responding and nonresponding patients with metastatic GCT.

**FIGURE 3.** A 31-y-old man with advanced nonseminomatous GCT. (A–C) Before chemotherapy, $^{18}$F-FDG PET/CT (A) and $^{18}$F-FLT PET/CT (B) show focally increased heterogeneous tracer uptake by abdominal metastasis (arrows), and CT scan (C) shows heterogeneous mass with tumor and necroses. (D–F) After 1 cycle of chemotherapy (early response), tumor shows decreased uptake of $^{18}$F-FDG (D) and $^{18}$F-FLT (E) and foci of residual viability, and CT scan (F) shows only minor reduction of tumor size and necroses. (G–I) After completion of chemotherapy, tumor shows persistent slightly focally increased $^{18}$F-FDG uptake (G), suggestive of viable residual tumor, but normal $^{18}$F-FLT distribution (H), and CT scan (I) shows bulky residual mass of unknown viability. Histology of secondary resection revealed highly differentiated teratoma with yolk sac tumor (Fig. 4). Six months after completion of therapy, relapse occurred.



between the MIB proliferation index and $\Delta^{18}$F-FDG SUVmean after therapy ($r = 0.81$, $P = 0.025$).

## DISCUSSION

With cisplatin-based combination chemotherapy, most patients with metastatic GCT can be cured today. Because not all patients will benefit to the same degree from this treatment, it is important to identify nonresponding patients early in the course of chemotherapy to avoid the side effects and high costs of an ineffective therapy. In patients with an unfavorable tumor marker decline, intensification of treatment using high-dose chemotherapy regimens with autologous stem cell support may be beneficial (4). In other tumors, such as lymphoma and breast carcinoma, $^{18}$F-FDG PET has been found to be an accurate predictor of

metabolic response after only 1 or 2 cycles of chemotherapy (26,27). In a previous study including patients with poor-prognosis GCT, we addressed this question and found that $^{18}$F-FDG PET was superior to CT and tumor marker decrease in predicting therapy response after chemotherapy, showing a high sensitivity but limited specificity (13). In the current investigation, all patients demonstrated a metabolic response on $^{18}$F-FDG and $^{18}$F-FLT PET according to EORTC criteria early after the first treatment cycle. However, when the early and final response assessments are compared on the basis of residual tumor histology or follow-up, the results are inconsistent for $^{18}$F-FDG and for $^{18}$F-FLT. In general, concerning the decrease of tumor uptake, there was no significant difference between responders and nonresponders for either tracer. However, in the $^{18}$F-FDG group, 4 of 11 patients showed false-positive

**FIGURE 4.** Histologic findings of mixed GCT (Fig. 3). (A) Yolk sac tumor before chemotherapy, with microvesicular growth pattern. Small cysts with thin walls are covered by flattened neoplastic epithelium. (Hematoxylin and eosin, ×200.) (B) Embryonal carcinoma before chemotherapy, with glandular and solid growth pattern. Cells of carcinoma show pleomorphic nuclei, numerous mitoses, and distinct cyto-



plasmatic borders with eosinophilic cytoplasm. (Hematoxylin and eosin, ×400.) (C) Resected retroperitoneal specimen after chemotherapy. Immature teratoma appears as multiple irregular cysts covered by intestinal, squamous, and bronchial epithelium (insert), in association with areas of pale basophilic cartilage, surrounded by immature mesenchymal spindle cell stroma. Minimal necrotic residues of yolk sac tumors are present, with no parts of embryonal carcinoma. (Hematoxylin and eosin, ×10.)

**TABLE 2.** Diagnostic Value of ^{18}F-FDG and ^{18}F-FLT for Prediction of Response According to Histology and Follow-up

| Timing of imaging | Tracer | Sensitivity | Specificity | Accuracy | PPV | NPV |
|---|---|---|---|---|---|---|
| After 1 chemotherapy cycle | ^{18}F-FDG | 3/5 (60%) | 2/6 (33%) | 5/11 (45%) | 3/7 (43%) | 2/4 (50%) |
| | ^{18}F-FLT | 3/5 (60%) | 4/5 (80%) | 7/10 (70%) | 3/4 (75%) | 4/6 (67%) |
| After end of chemotherapy | ^{18}F-FDG | 1/5 (20%) | 6/6 (100%) | 7/11 (64%) | 1/1 (100%) | 6/10 (60%) |
| | ^{18}F-FLT | 0/5 (0%) | 5/5 (100%) | 5/10 (50%) | 0/0 (0%) | 5/10 (50%) |

PPV = positive predictive value; NPV = negative predictive value.

results in the early evaluation that turned out to be necrosis on histologic examination or relapse-free survival on follow-up. False-positive results for ^{18}F-FDG PET during or shortly after chemotherapy, mainly due to an inflammatory process, are a known phenomenon because ^{18}F-FDG is not a tumor-specific agent (8). In contrast, ^{18}F-FLT as a marker of cellular proliferation has proven in preclinical studies to be a more cancer-specific tracer with only low uptake in inflammatory tissue (28,29). The evaluation of our patients revealed that all but one who was negative before treatment showed a substantial reduction of ^{18}F-FLT uptake during chemotherapy even early after the first cycle, but changes in ^{18}F-FLT uptake did not correlate with final outcome. Correlation with the proliferation index determined by immunohistochemical staining with MIB-1 revealed no specific increase in residual tumors, compared with adjacent fibrosis and inflammation. In contrast to studies on lung tumors and colorectal cancer (17,21), we did not find a significant correlation between the Ki-67 index and either ^{18}F-FLT uptake or ^{18}F-FDG uptake in the present study. Only the decrease of ^{18}F-FDG uptake has been found to correlate significantly with proliferation in these tumors. A reason for the lack of correlation between Ki-67 index and ^{18}F-FLT or ^{18}F-FDG uptake could be the inhomogeneous pathology of the disease itself. In fact, testicular cancer is a heterogeneous tumor, often mixed, and thus consisting of a variety of histologic layers (e.g., seminoma and non-seminoma parts, such as teratoma, teratocarcinoma, chorio-carcinoma, yolk sac tumors, or polyembryoma), which also vary from one patient to another. The histologic layers differ in growth pattern, differentiation, and proliferation with regard to malignant and well-differentiated components. The problem will become more evident in the postchemo-therapy assessment of such tumors with small residues of viable tumor in resected specimens, which are mainly scattered cells and small tubular structures, detected and classified by histologic examination only. These structures display a heterogeneous pattern of proliferative activity with foci of high mitotic activity and large areas of regression. Even here, proliferation can be matched in foam cells and lymphocytic follicles.

Another problem in the therapeutic management of metastasized GCT is that of residual masses remaining in 30%−40% of patients after completion of chemotherapy despite normalized tumor markers. The treatment of these residues remains difficult. To avoid unnecessary surgical resections (in cases of necrosis or fibrosis on histology), prediction of viability of these residual masses and differ-entiation between viable carcinoma, mature teratoma, and necrosis are important. So far, no diagnostic tool has been developed that reliably predicts the viability of residual masses. Established methods such as CT and serum tumor marker decline allow for an accuracy of 60%−70%, which is too low to avoid surgery. The results of our current study confirm the known limited role that has already been described for CT in classification of postchemotherapy residues (30–32). The authors of several investigations agree that ^{18}F-FDG PET predicts viable residual tumor with high diagnostic accuracy, except in small residuals. However, ^{18}F-FDG PET failed to differentiate mature teratoma from necrosis or fibrosis because both accumulate little or no ^{18}F-FDG (7,9,11,33). Therefore ^{18}F-FDG PET–negative residual tumors still require surgical resection. In our previous study, including 28 patients with mainly nonseminomatous poor-prognosis GCT, we confirmed the results of others demonstrating a high positive predictive value of 90% for ^{18}F-FDG PET but a low sensitivity of 62% and a low negative predictive value of 48% (32). The high percentage of nonseminoma patients with a false-negative PET result in the present study is striking, too. There was no difference between the tracers. In all but 1 patient, the untreated metastases were characterized by a distinct uptake of ^{18}F-FLT in the baseline examination. However, ^{18}F-FLT PET failed to detect the viable residuals in some patients with viable carcinoma or mature teratoma in histology. With ^{18}F-FDG PET, only 1 of those patients with an early relapse and residual malignancy on histology was correctly classified as positive. In contrast, the only seminoma patient was classified correctly as negative on both ^{18}F-FDG and ^{18}F-FLT in the early evaluation and in the final assessment after the end of therapy. Some investigators consider a teratoma-tous primary histology as the most important factor for the higher rate of false-negative ^{18}F-FDG PET findings in nonseminomas (34). The low sensitivity of ^{18}F-FLT for detection of viable residual tumor in our study may be related to the lower tissue uptake of ^{18}F-FLT than of ^{18}F-FDG in GCTs—a finding that has also been reported for several other tumors (17,19,21,29,35). It may be explained by a competition between ^{18}F-FLT and endogenous thymi-dine for uptake transporter and phosphorylation by thymidine

kinase 1 (*36*). Moreover, there are data demonstrating that ¹⁸F-FLT uptake and transport are determined not by thymidine kinase 1 activity alone but also by adenosine triphosphate levels (*37,38*). Therefore, the low ¹⁸F-FLT uptake in most of our patients may also have been caused by low adenosine triphosphate levels in the bulky GCT metastases. Another influencing factor may be the acquisition time, which was 60 min after injection in all our patients—probably not late enough for ¹⁸F-FLT. The poor correlation between the decrease of ¹⁸F-FLT during chemotherapy and the final response in our patients contrasts with the results of Pio et al. in breast cancer patients (*39*). This contrast may be related to the histopathologic differences in tumor type and chemotherapy regime, which may result in different relative contributions of the de novo and salvage pathways of DNA synthesis influencing ¹⁸F-FLT accumulation (*18,19,29,40*). Because of the lower tumor uptake, the usefulness of ¹⁸F-FLT for response monitoring in GCT seems to be a priori limited.

The small sample size of 11 patients in our pilot study including predominant nonseminomatous poor-prognosis GCT has to be regarded as a limitation. Any conclusions concerning the whole group of GCT patients, particularly those with less advanced clinical stages, can therefore be only limited. Another limitation is the method of validation, which was histology in only 7 of 11 of patients. In 4 patients the results were based largely on patient follow-up over at least 6 mo after the end of chemotherapy. However, because relapse or progression of GCT in high-risk patients can be expected soon after completion of therapy, our data seem valid even with this limitation.

## CONCLUSION

Our results show that despite the lower incidence of false-positive results with ¹⁸F-FLT PET than with ¹⁸F-FDG PET, PET-negative residual masses after chemotherapy of metastatic nonseminomatous GCT still require resection, because the low negative predictive value of ¹⁸F-FDG PET cannot be improved by application of the proliferation marker ¹⁸F-FLT. ¹⁸F-FLT did not correlate with Ki-67 or response. Positive results on ¹⁸F-FDG PET after chemotherapy correlated strongly with the presence of viable tumor. For prediction of response after completion of chemotherapy, the final PET scan, whether performed using ¹⁸F-FDG or using ¹⁸F-FLT, cannot be replaced by early response evaluation.

## ACKNOWLEDGMENTS

## REFERENCES

1. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. *J Clin Oncol.* 1997;15:594–603.
2. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. *JAMA.* 2008;299:672–684.
3. Hartmann JT, Gauler T, Metzner B, et al., for the German Testicular Cancer Study Group. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. *J Clin Oncol.* 2007;25:5742–5747.
4. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. *J Clin Oncol.* 2007;25:247–256.
5. Fossa SD, Aass N, Ous S, et al. Histology of tumor residuals following chemotherapy in patients with advanced non-seminomatous testicular cancer. *J Urol.* 1989;142:1239–1242.
6. Stomper PC, Kalish LA, Garnick MB, Richie JP, Kantoff PW. CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded? *Radiology.* 1991;180:711–714.
7. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. *J Clin Oncol.* 1996;14:1637–1641.
8. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnosis of oncological patients. *Eur J Nucl Med.* 1996;23:1409–1415.
9. Oechsle K, Hartmann M, Brenner W, et al. [F-18]fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German Multicenter Positron Emission Tomography Study group. *J Clin Oncol.* 2008;26:5930–5935.
10. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. *J Clin Oncol.* 2004;22:1034–1039.
11. Nuutinen JM, Leskinen S, Elomaa I, et al. Detection of residual tumors in postchemotherapy testicular cancer by FDG-PET. *Eur J Cancer.* 1997;33:1234–1241.
12. Hain SF, O'Doherty M, Timothy A, Leslie M, Harper P, Huddart R. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumors at relapse. *Br J Cancer.* 2000;83:863–869.
13. Pfannenberg AC, Oechsle K, Kollmannsberger C, et al. Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [¹⁸F]FDG-PET, CT or MRI, and tumor marker [in German]. *Rofo.* 2004;176:76–84.
14. Bokemeyer C, Kollmannsberger C, Oechsle K, et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [¹⁸F]-FDG-PET. *Br J Cancer.* 2002;86:506–511.
15. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. *Nat Med.* 1998;4:1334–1336.
16. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. *J Nucl Med.* 2002;43:1210–1217.
17. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: ¹⁸F-FLT versus ¹⁸F-FDG. *J Nucl Med.* 2003;44:1426–1431.
18. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [¹⁸F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. *Eur J Nucl Med Mol Imaging.* 2007;34:878–883.
19. Van Westreenen HL, Cobben DC, Jager PL, et al. Comparison of ¹⁸F-FLT PET and ¹⁸F-FDG PET in esophageal cancer. *J Nucl Med.* 2005;46:400–404.
20. Yamamoto Y, Nishiyama Y, Kimura N, et al. Comparison of ¹⁸F-FLT PET and ¹⁸F-FDG PET for preoperative staging in non-small cell lung cancer. *Eur J Nucl Med Mol Imaging.* 2008;35:236–245.
21. Francis DL, Visvikis D, Costa DC, et al. Potential impact of [¹⁸F]3′-deoxy-3′-fluorothymidine versus [¹⁸F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. *Eur J Nucl Med Mol Imaging.* 2003;30:988–994.
22. Hartmann JT, Rick O, Oechsle K, et al. Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. *Ann Surg.* 2005;242:260–266.
23. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C. Comparison of histological results from the resection of residual masses at

different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. *Eur J Cancer.* 1997;33:843–847.

24. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). *J Radioanal Nucl Chem.* 2000;243:843–846.

25. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. *Eur J Cancer.* 1999;35:1773–1782.

26. Schelling M, Avril N, Nährig J, et al. Positron emission tomography using F-18-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. *J Clin Oncol.* 2000;18:1689–1695.

27. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. *J Nucl Med.* 2002;43:1018–1027.

28. Van Waarde A, Cobben DCP, Suurmeijer AJH, et al. Selectivity of 3′-deoxy-3′-[18F]fluorothymidine (FLT) and 2-[18F]fluoro-2-deoxy-D-glucose (FDG) for tumor versus inflammation in a rodent model. *J Nucl Med.* 2004;45:695–700.

29. Been LB, Suurmeijer AJ, Cobben DCP, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. *Eur J Nucl Med Mol Imaging.* 2004;31:1659–1672.

30. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. *Ann Oncol.* 1997;8:531–538.

31. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. *J Clin Oncol.* 2003;21:3310–3317.

32. Pfannenberg AC, Oechsle K, Bokemeyer C, et al. The role of [F-18] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in metastatic germ cell tumors: prospects for management. *World J Urol.* 2004;22:132–139.

33. Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. *J Nucl Med.* 1998;39:815–822.

34. Steyerberg EW, Keizer HJ, Stoter G, Habbema JD. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. *Eur J Cancer.* 1994;30:1231–1239.

35. Quon A, Chang ST, Chin F, et al. Initial evaluation of F-18-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. *Eur J Nucl Med Mol Imaging.* 2008;35:527–531.

36. Kong XB, Zhu Qy, Vidal PM, Watanabe KA, Polsky B, Armstrong D. Comparison of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. *Antimicrob Agents Chemother.* 1992;36:808–818.

37. Barthel H, Cleij MC, Collingridge DR, et al. 3′-deoxy-3′[F-18]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. *Cancer Res.* 2003;63:3791–3798.

38. Dimitrakopoulou-Strauss A, Strauss LG. The role of F-FLT in cancer imaging: does it really reflect proliferation? *Eur J Nucl Med Mol Imaging.* 2008;35:523–526.

39. Pio BS, Park CK, Petras R, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. *Mol Imaging Biol.* 2006;8:36–42.

40. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. *Eur J Nucl Med Mol Imaging.* 2002;29:1462–1469.

# The Journal of NUCLEAR MEDICINE

# PET/CT with $^{18}$F-FLT: Does It Improve the Therapeutic Management of Metastatic Germ Cell Tumors?

Christina Pfannenberg, Philip Aschoff, Helmut Dittmann, Frank Mayer, Gerald Reischl, Claus von Weyhern, Lothar Kanz, Claus D. Claussen, Roland Bares and Joerg T. Hartmann

This article and updated information are available at:
**http://jnm.snmjournals.org/content/51/6/845**

Information about reproducing figures, tables, or other portions of this article can be found online at:
**http://jnm.snmjournals.org/site/misc/permission.xhtml**

Information about subscriptions to JNM can be found at:
**http://jnm.snmjournals.org/site/subscriptions/online.xhtml**

SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING